Ono Pharmaceutical (United Kingdom)

Safety and Clinical Activity of Pembrolizumab and Multisite Stereotactic Body Radiotherapy in Patients With Advanced Solid Tumors

Jason J. Luke, Jeffrey M. Lemons, Theodore Karrison et al. · Journal of Clinical Oncology · 2018 · 574 citations

A phase 1 clinical trial of the selective BTK inhibitor ONO/GS-4059 in relapsed and refractory mature B-cell malignancies

Harriet S. Walter, Simon A. Rule, Martin J.S. Dyer et al. · Blood · 2015 · 262 citations · Full text

Safety and efficacy of the cathepsin K inhibitor ONO-5334 in postmenopausal osteoporosis: The OCEAN study

Richard Eastell, Shinichi Nagase, Michiyo Ohyama et al. · Journal of Bone and Mineral Research · 2011 · 126 citations

Effect of ONO-5334 on Bone Mineral Density and Biochemical Markers of Bone Turnover in Postmenopausal Osteoporosis: 2-Year Results From the OCEAN Study

Richard Eastell, Shinichi Nagase, Maria Small et al. · Journal of Bone and Mineral Research · 2013 · 75 citations

Inhibition of cell proliferation by nobiletin, a dietary phytochemical, associated with apoptosis and characteristic gene expression, but lack of effect on early rat hepatocarcinogenesis <i>in vivo</i>

Hiroyuki Ohnishi, Makoto Asamoto, Kazunari Tujimura et al. · Cancer Science · 2004 · 70 citations · Full text